Navigation Links
R-Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0.15% UF-021
Date:8/24/2009

TOKYO, Aug. 25 /PRNewswire/ -- We are pleased to announce that subject enrollment for the phase 2 clinical study of 0.15% UF-021 (generic name; isopropyl unoprostone; active ingredient of Rescula(R) eye-drops) in patients with retinitis pigmentosa has been completed.

We submitted the notification of the clinical trial in August 2008. Enrollment in the phase 2 study began at six clinical sites in late December 2008 and was completed on August 3, 2009.

The clinical study has progressed with no delay, no serious adverse effects, and only a few cases of discontinuation so far. Hereafter, we expect to complete the study by next spring, including data collection and analysis.

Retinitis pigmentosa is a progressive hereditary disease affecting nearly 50,000 people in Japan, which is characterized by night blindness. Patients generally suffer from peripheral visual field loss and low vision in the late stage of the disease. At present, there is no effective treatment for this disease.

We developed and launched isopropyl unoprostone eye-drops on the market as a drug for glaucoma and ocular hypertension in 1994. In recent studies on isopropyl unoprostone, the drug has been reported to present neuroprotective effects and a function to improve ocular circulation. Studies at some university hospitals have also suggested that isopropyl unoprostone eye-drops improve symptoms of retinitis pigmentosa or stop the progression of the disease.

We expect isopropyl unoprostone to become a unique drug for improvement of the quality of vision in patients with retinitis pigmentosa.

About R-Tech Ueno, Ltd.

R-Tech Ueno was established in September 1989 for the purpose of marketing and R&D of drugs. Under the leadership of the president, also a medical doctor, the company is developing new drugs on the theme "Physician-Oriented New Drug Innovation," targeting ophthalmologic and dermatologic diseases that previously had no effective therapeutic agent.

The company's main product Rescula(R) eye-drops 0.12% is a therapeutic drug for glaucoma and ocular hypertension and has been marketed in Japan since 1994. R-Tech Ueno was the first in the world to take advantage of the substance "prostone" in the development of Rescula(R). Prostone was discovered in 1980 by Dr. Ryuji Ueno, the founder of the company.

Rescula(R) eye-drops 0.12% that causes less topical and systemic adverse reactions, demonstrates steady ocular pressure decreasing action by twice-a-day instillation. Such excellent therapeutic effects are realized through its optic nerve protection and ocular blood flow-increasing mechanism.

Concerning Rescula(R) (isopropyl unoprostone) for the treatment of glaucoma and ocular hypertension, R-Tech Ueno concluded a contract with Sucampo Pharma Americas, Inc. in April 2009 for the approval and assignment of distributorship, as well as for licensing the relevant patents and granting exclusive right to manufacture and supply in the USA and Canada.


    Representative Director & President: Yukihiko Mashima
    Head Office: 1-1-7 Uchisaiwai-cho, Chiyoda-ku, Tokyo
    Code No.4573, Osaka Securities Exchange; Hercules

    Contact:
    Koji Nakamura
    Business Management Department
    R-Tech Ueno, Ltd.
    Tel: +81-3-3596-8011
    e-mail: koji.nakamura@rtueno.co.jp


'/>"/>
SOURCE R-Tech Ueno, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
2. ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology
3. SIRO Clinpharm Completes Successful Implementation of Oracle Life Sciences Application Suite
4. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
5. Osteotech Completes Enrollment for DuraTech(TM) BioRegeneration Matrix Clinical Trial
6. Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
7. Potentia Pharmaceuticals POT-4 Drug Candidate for Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial - Prepares for Phase II
8. Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
9. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
10. Major Restless Legs Study Completes Enrollment With Support From MediciGlobal
11. QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... , May 4, 2017  A recent study ... Ultraviolet-C light as a means of ... ability to reduce bioburden on anesthesia workstations. In ... on high-touch, complex medical equipment surfaces contaminated with ... "This study further validates the body ...
(Date:5/4/2017)... WAYNE, Pa. , May 4, 2017 /PRNewswire/ ... made from thermoplastics and other highly-engineered materials, is ... Microextrusion tubing has been developed in recent ... neurovascular interventional therapies and surgical applications. More expensive ... used to produce microextrusion tubing due to their ...
(Date:5/3/2017)... May 3, 2017  Getinge, a leading global ... quality enhancement and cost efficiency within healthcare and ... of contemporary practice demonstrating that intra-aortic balloon counterpulsation ... critically ill patients. The single-center, retrospective, observational study ... volume MEGA ® 50cc intra-aortic balloon (IAB) ...
Breaking Medicine Technology:
(Date:5/24/2017)... , ... May 24, 2017 , ... ... of ExtraHop to its solutions portfolio. ExtraHop delivers an analytics-first approach, layered with ... every IT system, from the datacenter to the cloud to the edge. Through ...
(Date:5/24/2017)... ... 24, 2017 , ... Fiberstar, Inc., http://www.FiberstarIngredients.com a ... beverage industry offers Citri-Fi®, a natural citrus fiber, to improve beverage ingredient declarations. ... a result, labels need to deliver simple, transparent and clear messaging. Listed food ...
(Date:5/23/2017)... ... , ... Allegheny Health Network and the Alexis Joy D’Achille ... Behavioral Health at West Penn Hospital , a unique facility that will offer ... depression. Construction of the Center is underway with a scheduled opening in the ...
(Date:5/23/2017)... ... 2017 , ... The National Council on Strength and Fitness ... organization’s Certified Strength Coach credential has earned accreditation from the National Commission for ... competency of qualified candidates for jobs in the Strength and Conditioning profession. The ...
(Date:5/23/2017)... New York (PRWEB) , ... May 23, 2017 ... ... NextGen LifeLabs, a leading equipment provider in the modern ART laboratory, to provide ... Institute in Ft. Lauderdale, Florida. , NextGen LifeLabs, a MedTech Group Purchasing ...
Breaking Medicine News(10 mins):